繁體
简体中文
繁體中文

Kura Oncology KURA 深 滬

已收盤 11-20 16:00:00 美东时间

6.91

-0.440

-5.99%

华盛通華盛通
立即下載
  • 最 高7.37
  • 今 開7.13
  • 成交量 175.25万股
  • 最 低 6.89
  • 昨 收 7.35
  • 總市值 6.35亿
  • 52周最高 13.90
  • 市盈率 靜 --
  • 換手率 1.91%
  • 52周最低 6.75
  • 委 比 49.13%
  • 總股本 9187.87万
  • 歷史最高 43.00
  • 量 比 0.72
  • 振 幅 6.53%
  • 歷史最低 2.50
  • 每 手 1
  • 風險率 1.40%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Kura Oncology Inc收跌2%,成交额1874.68万美元

    11月19日,Kura Oncology Inc(KURA)收跌2%,报7.34美元,成交额1874.68万美元,市值6.74亿美元。 行情数据 • 开盘价:...

    11-19 06:56

  • Kura Oncology to Participate in Two Investor Conferences in November

    Kura Oncology announced that its management will present at two investor conferences: the UBS Global Biopharma London Conference on November 17, 2026, and the Jefferies Global Healthcare Conference on November 18, 2026. Live audio webcasts will be available on Kura’s website, with archived replays following the events. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, with a pipeline targeting cance...

    11-13 17:33

  • Kura Oncology Inc收平,成交额1882.43万美元

    11月11日,Kura Oncology Inc(KURA)收平,报7.57美元,成交额1882.43万美元,市值6.73亿美元。 行情数据 • 开盘价:7....

    11-11 06:55

  • Kura Oncology Files Shelf Prospectus For Offering; Size Not Disclosed

    Kura Oncology Files Shelf Prospectus For Offering; Size Not Disclosed

    11-11 06:22

  • Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update

    Kura Oncology reported strong Q3 2026 performance with KOMZIFTI net product revenue up 53% to $13.9M, new patient starts up 30%, and total prescriptions up 65%. KOMZIFTI maintained majority share in the R/R NPM1-m AML market. The company advanced ziftomenib into frontline AML and reached FDA alignment on a darlifarnib registrational study for HRAS-mutant salivary gland cancer. Financially, Kura has $492.1M in cash and secured up to $300M addition...

    11-10 21:02

  • Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Kura Oncology granted inducement stock options to three new employees under its 2023 Inducement Option Plan. The options, totaling 55,500 shares with an exercise price of $9.79 per share, vest over four years, with 25% vesting after one year and the remainder vesting monthly over the next 36 months. The grant aligns with Nasdaq Listing Rule 5635(c)(4).

    11-06 12:30

  • Kura Oncology Inc收跌22.98%,成交额6710.41万美元

    11月5日,Kura Oncology Inc(KURA)收跌22.98%,报7.61美元,成交额6710.41万美元,市值6.77亿美元。 行情数据 • 开盘...

    11-05 06:57

  • MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors

    MacroGenics, Inc. announced the appointment of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors to its Board of Directors, effective October 30, 2026. Both bring extensive oncology drug development experience, which will support the company's pipeline advancement and long-term strategic goals. Dr. Kuriakose has over a decade of experience in oncology and metabolic disease drug development, most recently as Chief Medica...

    11-03 21:05

  • Kura Oncology to Report Third Quarter Financial Results on November 10

    Kura Oncology announced it will report third quarter 2026 financial results after market close on November 10, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. The live webcast and archived replay will be available on the Company’s website. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer, with a pipeline targeting c...

    11-03 11:58

  • Kura Oncology Inc收涨8.28%,成交额2392.15万美元

    10月29日,Kura Oncology Inc(KURA)收涨8.28%,报10.72美元,成交额2392.15万美元,市值9.54亿美元。 行情数据 • 开...

    10-29 05:46